JP2019522032A - 前立腺癌の治療方法 - Google Patents

前立腺癌の治療方法 Download PDF

Info

Publication number
JP2019522032A
JP2019522032A JP2019504790A JP2019504790A JP2019522032A JP 2019522032 A JP2019522032 A JP 2019522032A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019522032 A JP2019522032 A JP 2019522032A
Authority
JP
Japan
Prior art keywords
prostate cancer
nilaparib
treatment
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019504790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522032A5 (https=
Inventor
ゴッタルディス，マルコ
ホーキンス，レベッカ
スナイダー，リンダ
エイチ． ヤマダ，ダグラス
エイチ． ヤマダ，ダグラス
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59649991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019522032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2019522032A publication Critical patent/JP2019522032A/ja
Publication of JP2019522032A5 publication Critical patent/JP2019522032A5/ja
Priority to JP2022084991A priority Critical patent/JP7569353B2/ja
Priority to JP2024117499A priority patent/JP7752220B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504790A 2016-07-29 2017-07-28 前立腺癌の治療方法 Withdrawn JP2019522032A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022084991A JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US62/368,466 2016-07-29
US201662369239P 2016-08-01 2016-08-01
US62/369,239 2016-08-01
PCT/US2017/044413 WO2018023017A1 (en) 2016-07-29 2017-07-28 Methods of treating prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084991A Division JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Publications (2)

Publication Number Publication Date
JP2019522032A true JP2019522032A (ja) 2019-08-08
JP2019522032A5 JP2019522032A5 (https=) 2020-09-03

Family

ID=59649991

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504790A Withdrawn JP2019522032A (ja) 2016-07-29 2017-07-28 前立腺癌の治療方法
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A Active JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A Active JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Country Status (33)

Country Link
US (8) US20180028521A1 (https=)
EP (2) EP4552698A3 (https=)
JP (3) JP2019522032A (https=)
KR (2) KR20190033599A (https=)
CN (3) CN109640991A (https=)
AU (2) AU2017302660B2 (https=)
BR (1) BR112019001398A2 (https=)
CA (1) CA3031705A1 (https=)
CO (1) CO2019000753A2 (https=)
CY (2) CY1127713T1 (https=)
DK (1) DK3490560T3 (https=)
DO (1) DOP2019000019A (https=)
ES (1) ES3014630T3 (https=)
FI (2) FI3490560T3 (https=)
FR (1) FR25C1027I1 (https=)
HR (1) HRP20250157T1 (https=)
HU (2) HUE070253T2 (https=)
IL (2) IL322013A (https=)
LT (2) LT3490560T (https=)
MA (1) MA45780B1 (https=)
MX (2) MX2019001224A (https=)
NI (1) NI201900009A (https=)
PE (1) PE20190403A1 (https=)
PH (1) PH12019500135A1 (https=)
PL (1) PL3490560T3 (https=)
PT (1) PT3490560T (https=)
RS (1) RS66574B1 (https=)
SG (1) SG11201900361RA (https=)
SI (1) SI3490560T1 (https=)
SM (1) SMT202500082T1 (https=)
SV (1) SV2019005822A (https=)
UA (1) UA124972C2 (https=)
WO (1) WO2018023017A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
SG11202006147SA (en) * 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
EP3793541A4 (en) * 2018-05-16 2022-03-02 GTx, Inc. ANDROGEN RECEPTOR DEGRADER (SARD) SELECTIVE LIGANDS AND METHODS OF USE THEREOF
WO2020051344A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20240325369A1 (en) * 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
DE4021433A1 (de) 1990-07-04 1992-01-09 Schering Ag Antiandrogene mit steroid(3,2-c)pyrazol-struktur
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
EP0721461B1 (en) 1993-09-30 1999-02-03 Btg International Limited Synthesis of 17-(3-pyridyl) steroids
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
WO1997044026A1 (en) 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
EP1276482B1 (en) 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
US6953785B2 (en) 2000-04-24 2005-10-11 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives
BR0110877A (pt) 2000-05-15 2003-03-11 Celgene Corp Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
EP1676577A1 (en) 2000-05-15 2006-07-05 Celgene Corporation Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
CN1254234C (zh) 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
AU2000260772A1 (en) 2000-07-05 2002-01-14 Bryan Muehlberger Systems and methods of facilitating electronic payment transactions
AU2002226877B2 (en) 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
EP1351678A2 (en) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
NZ551453A (en) 2001-04-18 2008-02-29 Euro Celtique Sa Nociceptin analogs for the treatment of pain
KR100628292B1 (ko) 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
US6872733B2 (en) 2001-04-18 2005-03-29 Euro-Celtique S.A. Benzimidazolone compounds
PT1385514E (pt) 2001-04-18 2009-02-04 Euro Celtique Sa Compostos espiroindeno e espiroindano
WO2002091993A2 (en) 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
WO2003020699A2 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
WO2003066595A2 (en) 2002-02-01 2003-08-14 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
EP1488807A4 (en) 2002-03-11 2009-07-08 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES
CA2481241C (en) 2002-04-08 2010-07-27 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
EP1927858B1 (en) 2002-04-29 2013-01-09 Euro-Celtique S.A. Conformationally constrained peptides that bind the ORL-1 receptor
WO2003092595A2 (en) 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
ES2282647T3 (es) 2002-06-14 2007-10-16 MERCK & CO., INC. Inhibidores de cinesina mitotica.
PT1556354E (pt) 2002-06-28 2008-04-17 Euro Celtique Sa Derivados de piperazina úteis como agentes terapêuticos para o tratamento da dor
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
EP1534336A4 (en) 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AU2003274823A1 (en) 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CA2503715A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
MXPA05006485A (es) 2002-12-17 2005-08-26 Schering Corp Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno.
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
JP2006515623A (ja) 2003-01-13 2006-06-01 セダーズ−シナイ メディカル センター 化学療法剤としてのパリカルシトール
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1867644T1 (sl) 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PL1942106T3 (pl) 2003-08-01 2012-02-29 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
CN1842515A (zh) 2003-08-27 2006-10-04 默克弗罗斯特加拿大有限公司 组织蛋白酶抑制剂
EP1664041B1 (en) 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
PL1664016T3 (pl) 2003-09-22 2009-04-30 Euro Celtique Sa Środki terapeutyczne przydatne do leczenia bólu
CA2537224A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
US7445794B1 (en) 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
AU2005281797B2 (en) 2004-09-10 2011-07-07 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
EP1674479A1 (en) 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
WO2006116716A2 (en) 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
EP1877060A2 (en) 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
EP2007733B1 (en) 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008039254A2 (en) 2006-06-02 2008-04-03 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rna nanoparticles and nanotubes
CA2656393A1 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051375A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
EP2081964A4 (en) 2006-10-12 2012-07-11 Univ Johns Hopkins ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
US20100168228A1 (en) 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
BRPI0807812A2 (pt) 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
WO2008109740A2 (en) 2007-03-06 2008-09-12 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
WO2009009132A1 (en) 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
LT2278975T (lt) 2008-05-07 2016-11-25 Cardioxyl Pharmaceuticals Inc. Nauji nitrozo junginiai kaip nitroksilo donorai, ir jų panaudojimo būdas
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
SG11201501870RA (en) * 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
WO2014150000A1 (en) 2013-03-21 2014-09-25 Isp Investments Inc. Diacetylene film sensitized with photoinitiator and applications of the film
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA2920317A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015164586A1 (en) 2014-04-23 2015-10-29 The Brigham And Women's Hospital, Inc. Targeting parp1 for treatment of tsc and cancers
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
US11702443B2 (en) 2016-10-04 2023-07-18 Pop Test Oncology Llc Therapeutic agents and methods
US11040037B2 (en) 2016-10-04 2021-06-22 Pop Test Oncology Llc Therapeutic agents and methods
WO2018191141A1 (en) 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
EP3694604A1 (en) 2017-10-11 2020-08-19 Janssen Oncology, Inc. Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUGS OF THE FUTURE, vol. 38, no. 10, JPN6021015328, 2013, pages 679 - 685, ISSN: 0004493217 *
LANCET ONCOL, vol. 14, JPN6021015330, 2013, pages 882 - 892, ISSN: 0004493218 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 373, no. 18, JPN6021015333, 2015, pages 1697 - 1708, ISSN: 0004493219 *

Also Published As

Publication number Publication date
US20180028521A1 (en) 2018-02-01
WO2018023017A1 (en) 2018-02-01
HUS2500030I1 (hu) 2025-08-28
HUE070253T2 (hu) 2025-05-28
IL322013A (en) 2025-09-01
HRP20250157T1 (hr) 2025-03-28
EP4552698A2 (en) 2025-05-14
ES3014630T3 (en) 2025-04-23
NI201900009A (es) 2019-05-10
KR20240115925A (ko) 2024-07-26
MX2019001224A (es) 2019-06-03
FI3490560T3 (fi) 2025-02-27
PT3490560T (pt) 2025-03-20
SG11201900361RA (en) 2019-02-27
CY1127713T1 (el) 2026-02-25
CO2019000753A2 (es) 2019-02-08
RS66574B1 (sr) 2025-03-31
US11207311B2 (en) 2021-12-28
US20230098047A1 (en) 2023-03-30
CN119606966A (zh) 2025-03-14
US11986470B2 (en) 2024-05-21
MA45780B1 (fr) 2025-03-28
EP3490560A1 (en) 2019-06-05
SV2019005822A (es) 2019-03-28
LTPA2025528I1 (https=) 2025-08-11
BR112019001398A2 (pt) 2019-05-07
US20240000766A1 (en) 2024-01-04
JP7752220B2 (ja) 2025-10-09
LT3490560T (lt) 2025-02-25
AU2023202813B2 (en) 2026-04-23
CN119606965A (zh) 2025-03-14
US20190022079A1 (en) 2019-01-24
US12383543B2 (en) 2025-08-12
CN109640991A (zh) 2019-04-16
AU2023202813A1 (en) 2023-05-25
US20230078160A1 (en) 2023-03-16
FIC20250026I1 (fi) 2025-07-21
AU2017302660B2 (en) 2023-04-20
US11992486B2 (en) 2024-05-28
SMT202500082T1 (it) 2025-03-12
JP2022122920A (ja) 2022-08-23
UA124972C2 (uk) 2021-12-22
CA3031705A1 (en) 2018-02-01
PL3490560T3 (pl) 2025-03-24
US20220071980A1 (en) 2022-03-10
MX2023011187A (es) 2023-10-02
DK3490560T3 (da) 2025-02-17
JP7569353B2 (ja) 2024-10-17
US11986469B2 (en) 2024-05-21
US11986468B2 (en) 2024-05-21
MA45780A (fr) 2019-06-05
US20230149380A1 (en) 2023-05-18
EP4552698A3 (en) 2025-07-30
CY2025021I1 (el) 2026-02-25
EP3490560B1 (en) 2025-01-22
PE20190403A1 (es) 2019-03-13
PH12019500135A1 (en) 2019-10-28
AU2017302660A1 (en) 2019-01-24
JP2024150638A (ja) 2024-10-23
SI3490560T1 (sl) 2025-04-30
KR20190033599A (ko) 2019-03-29
US20220071979A1 (en) 2022-03-10
IL264443A (en) 2019-02-28
FR25C1027I1 (fr) 2025-09-19
DOP2019000019A (es) 2019-09-30

Similar Documents

Publication Publication Date Title
JP7752220B2 (ja) 前立腺癌の治療方法
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
HK40126976A (en) Methods of treating prostate cancer
HK40126973A (zh) 治疗前列腺癌的方法
EA049291B1 (ru) Способы лечения рака предстательной железы
EA040279B1 (ru) Способы лечения рака предстательной железы
HK40007092A (en) Methods of treating prostate cancer
BR122024017981A2 (pt) Composição, forma de dosagem, produto e usos de niraparibe no tratamento de câncer de próstata
BR122024017955A2 (pt) Usos de niraparibe no tratamento de câncer de próstata metastático sensível à castração
US20250213563A1 (en) Substituted pyrimidin-4(3h)-ones for use in treating cancer
AU2024218635A1 (en) Use of tyrosine kinase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220525

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220607

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240219